<DOC>
	<DOCNO>NCT00973011</DOCNO>
	<brief_summary>The Phase Ia , open-label , multicenter study consist single-dose , dose-escalation study safety , tolerability , pharmacokinetics , immunogenicity intravitreal ( ITV ) injection FCFD4514S patient Geographic Atrophy ( GA ) .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics , Immunogenicity Intravitreal Injections FCFD4514S Patients With Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Ability willingness undertake schedule visit assessment Agreement use effective form contraception duration study Geographic atrophy ( GA ) least 0.75 disc area absence choroidal neovascularization ( CNV ) Treatment active systemic infection Predisposition history increase risk infection Active malignancy History medical condition , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication GA either eye due nonAMD cause Active history ocular intraocular condition study eye ( except GA ) History vitreoretinal surgery laser photocoagulation study eye Prior treatment AMD ( except vitamin mineral ) History intravitreal ( ITV ) drug delivery Intraocular surgery ( include cataract surgery ) study eye within 3 month precede Day 0 Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>GA</keyword>
</DOC>